Imaging Probe Translation Platform
Goals
- To develop efficient and standardized validation techniques for single- or multi-modality imaging probes, produced via nanotechnology/biotechnology means or conventional chemistry approaches; and
- To develop efficient in vitro and in vivo screening approaches that supports or rejects the use of the probe for the detection of very early cancers in preclinical models.
The Imaging Probe Translation portion of the Imaging Translation Platform has been established as the Centre for Probe Development and Commercialization (CPDC). It is jointly funded by OICR and the Networks of Centres of Excellence through the Centres of Excellence for Commercialization and Research Program. The focus of the Centre is development and commercialization of molecular imaging probes. The CPDC has the capability to produce agents to support drug discovery and develop novel agents to foster early detection of disease.
Lead Principal Investigator
Dr. John F. Valliant, McMaster University
Sub-Projects
- Probe Development and Commercialization
- Attracting Investment to Ontario and Company Creation
- Supporting Clinical Trials Applications
- Internal IP Generation
- Creation of an Imaging in Cancer Drug Development Program
- Creation and Application of the Ontario Molecular Imaging Agent Repository (OMIAR)
- Flow Chemistry as a New Probe Development Paradigm
- Launch Investigator Sponsored Research Competition